drugset / Trial / NCT00753896

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

NCT00753896

Phase 3 Completed 134 enrolled AstraZeneca Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks.

Timeline

Start
2008-10
Primary completion
2009-07
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 2 mg Subcutaneous